Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Evolving Pipeline of Treatments for Chronic Itch
Description
In a discussion on evolving treatments for chronic itch, the speaker highlights a range of emerging therapies, focusing on topical medications, biologics, and investigational drugs. They emphasize the need for effective topical treatments for conditions like chronic spontaneous urticaria and atopic eczema, noting the promise of JAK inhibitors such as roxolitinib and delgositinib, which show rapid effects on itch reduction. The conversation includes advancements in peptide 4 inhibitors, specifically crisaborole for subdermatitis, and mentions newer targets like TRPV channels and their involvement in itch mechanisms. The speaker also addresses the advent of biologics like dupilumab, lebrikizumab, and nemolizumab, which target interleukins associated with itch and have shown significant improvements in clinical trials. They stress the potential for these treatments to address unmet needs in geriatric populations and other patient groups with complex dermatological conditions. Additionally, they touch upon the role of small fibers and neuropathic itch, suggesting ongoing and future clinical trials could provide further insights into effective therapies. The talk concludes with a hopeful outlook on numerous investigational drugs currently in development for itch, reflecting significant growth in treatment options compared to previous years.
View moreConclusions
- There is a growing need for effective topical treatments for itch, particularly for chronic conditions.
- Janus kinase inhibitors, such as Ruxolitinib and Delgocitinib, show significant efficacy in treating various itch-related skin conditions.
- Topical PDE4 inhibitors like Roflumilast and Crisaborole demonstrate improved antipruritic effects over placebo and are effective for atopic dermatitis and seborrheic dermatitis.
- New biologics, including Dupilumab, Lebrikizumab, and Nemolizumab, are showing promising results in controlling itch in atopic dermatitis and chronic spontaneous urticaria.
- Targeting specific cytokines, such as IL-31, has proven effective in reducing itch and improving quality of life in affected patients.
- The emerging research on drugs that inhibit MRGPRX2 represents a novel approach to treating mast cell-related itch and highlights the need for continued exploration of non-histaminergic pathways.
- Ketamine infusions have shown potential for treating intractable neuropathic itch by altering neuroplasticity in the brain.
- Overall, the conclusion underscores the importance of monotherapy and combined approaches in the management of chronic itch, emphasizing the diverse underlying mechanisms that contribute to this symptom.
- Brumfield et al. JID 2022
- Zhu et al. JEADV 2023
- Bauer et al. Contact Derm 2023
- Blauvelt A. J Am Acad Dermatol. 2023. DOI: 10.1016/j.jaad.2022.09.010
- Zirwas et al. JAMA Derm 2023
- Silverberg et al. AAAA 2024
- Yosipovitch G, Rosen JD, Hashimoto T. J Allergy Clin Immunol. 2018. DOI: 10.1016/j.jaci.2018.09.005
- Simpson EL. JAMA Dermatol. 2023. DOI: 10.1001/jamadermatol.2022.5534
- Yosipovitch G. Br J Dermatol. 2024. DOI: 0.1093/bjd/ljad435
- Silverberg JI. J Eur Acad Dermatol Venereol. 2021. DOI: 10.1111/jdv.17218
- Rosen JD, Fostini AC, Yosipovitch G. Diagnosis and Management of Neuropathic Itch. Dermatol Clin. 2018 Jul;36(3):213-224
- Kwatra SG, Kambala A, Cornman H, Reddy SV, Cohen SP. Ketamine Infusions for Treatment-Resistant Neuropathic Pruritus. JAMA Dermatol. Published online August 02, 2023.
- Sutaria N. J Am Acad Dermatol. 2022. DOI: 10.1016/j.jaad.2021.07.078
- Kolkhir P, et al. Ann Allergy Asthma Immunol. 2020;124:2-12.